ENTRY       D10808                      Drug
NAME        Durvalumab (USAN/INN);
            Durvalumab (genetical recombination) (JAN);
            Imfinzi (TN)
PRODUCT     IMFINZI (AstraZeneca Pharmaceuticals LP)
SEQUENCE    (Heavy chain)
            EVQLVESGGG LVQPGGSLRL SCAASGFTFS RYWMSWVRQA PGKGLEWVAN IKQDGSEKYY
            VDSVKGRFTI SRDNAKNSLY LQMNSLRAED TAVYYCAREG GWFGELAFDY WGQGTLVTVS
            SASTKGPSVF PLAPSSKSTS GGTAALGCLV KDYFPEPVTV SWNSGALTSG VHTFPAVLQS
            SGLYSLSSVV TVPSSSLGTQ TYICNVNHKP SNTKVDKRVE PKSCDKTHTC PPCPAPEFEG
            GPSVFLFPPK PKDTLMISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY
            NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK ALPASIEKTI SKAKGQPREP QVYTLPPSRE
            EMTKNQVSLT CLVKGFYPSD IAVEWESNGQ PENNYKTTPP VLDSDGSFFL YSKLTVDKSR
            WQQGNVFSCS VMHEALHNHY TQKSLSLSPG K
            (Light chain)
            EIVLTQSPGT LSLSPGERAT LSCRASQRVS SSYLAWYQQK PGQAPRLLIY DASSRATGIP
            DRFSGSGSGT DFTLTISRLE PEDFAVYYCQ QYGSLPWTFG QGTKVEIKRT VAAPSVFIFP
            PSDEQLKSGT ASVVCLLNNF YPREAKVQWK VDNALQSGNS QESVTEQDSK DSTYSLSSTL
            TLSKADYEKH KVYACEVTHQ GLSSPVTKSF NRGEC
            (Disulfide bridge: H22-H96, H148-H204, H224-L215, H230-H'230, H233-H'233, H265-H325, H371-H429, H'22-H'96, H'148-H'204, H'224-L'-225, H'265-H'325, H'371-H'429, L23-L89, L135-L195, L'23-L'89, L'135-L'195)
  TYPE      Peptide
CLASS       Antineoplastic
             DG02938  Immune checkpoint inhibitor
REMARK      Therapeutic category: 4291
            ATC code: L01FF03
            Product: D10808<JP/US>
EFFICACY    Antineoplastic, Anti-PD-L1 antibody
  DISEASE   Non-small cell lung cancer [DS:H00014]
            Small cell lung cancer [DS:H00013]
            Biliary tract cancers [DS:H00046 H00047]
            Hepatocellular carcinoma [DS:H00048]
  TYPE      Monoclonal antibody
TARGET      PDL1 (CD274) [HSA:29126] [KO:K06745]
  PATHWAY   hsa04514(29126)  Cell adhesion molecules
            hsa05235(29126)  PD-L1 expression and PD-1 checkpoint pathway in cancer
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L01 ANTINEOPLASTIC AGENTS
               L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
                L01FF PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors
                 L01FF03 Durvalumab
                  D10808  Durvalumab (USAN/INN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Antineoplastics
              Monoclonal Antibody/Antibody-Drug Conjugate
               Durvalumab
                D10808  Durvalumab (USAN/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             4  Agents affecting cellular function
              42  Antineoplastics
               429  Miscellaneous
                4291  Other Antitumors
                 D10808  Durvalumab (USAN/INN); Durvalumab (genetical recombination) (JAN)
            Drug groups [BR:br08330]
             Antineoplastic
              DG02938  Immune checkpoint inhibitor
               D10808  Durvalumab
            Drug classes [BR:br08332]
             Antineoplastic
              DG02938  Immune checkpoint inhibitor
               D10808  Durvalumab
            Target-based classification of drugs [BR:br08310]
             Cell surface molecules and ligands
              Other cell surface molecules
               Immune checkpoints
                PDL1 (CD274)
                 D10808  Durvalumab (USAN/INN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D10808
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D10808
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D10808
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D10808
            Pharmacogenomic biomarkers [br08341.html]
             Somatic variations in targeted cancer therapies
              D10808
DBLINKS     CAS: 1428935-60-7
            PubChem: 319075068
///
